Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial - Yanling Wu; Yuan Li; Ping Zhang; Siwei Guo; Fang Yuan; Vivian Liu; Ting Yu; Feng Lin; Nan Yang; Chao Tu; Hongzhou Lu; Tianlei Ying; et al. (Cell Discovery)